Impact of Using Abdominal Circumference Independently in the Diagnosis of Fetal Growth Restriction

Abstract

adequately powered to find a difference. In addition, there was inadequate data to demonstrate differential benefits in different moderate-and high-risk populations. Thus, the current recommendation continues to be for a single daily dose of less than 100 mg, which in the United States is the 81-mg tablet. Over time, what remains to be sorted out are the exact population to treat and whether there is an optimal timing or dosage, meanwhile, unless you are offering LDA to everyone, an approach to identify all patients with increased risk should be implemented.-ABC)